The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Chromosome translocations in multiple myeloma
Abstract
Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3' enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 40% of multiple myeloma is characterized by the presence of trisomies in the neoplastic plasma cells (hyperdiploid multiple myeloma), while most of the rest have a translocation involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 (IgH translocated multiple myeloma).38–41”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [39]
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Cancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,900
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Anderson, P. C. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.24.2351 · Cited by 1,006
Cellular Origin of Human B-Cell Lymphomas
Küppers, R., Klein, U., Hansmann, M.-L., & Rajewsky, K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911113412007 · Cited by 715
The Proto-Oncogene c-maf Is Responsible for Tissue-Specific Expression of Interleukin-4
Ho, I.-C., Hodge, M. R., Rooney, J. W., & Glimcher, L. H. (1996) · Cell · doi:10.1016/s0092-8674(00)81299-4 · Cited by 667
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637 · cited 2×
“…of conventional cytogenetics, SKY analyses, metaphase FISH analyses, isolation of molecular clones, and RT±PCR assays (Bergsagel et al., 1996; Chesi et al., 1997, 1998a; Gabrea et al., 1999; Shaughnessy et al., 2001; Shou et al., 2000; Kuehl, 2001, unpublished results), we have identi®ed at…”
BackgroundSelf-citationChesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W. M., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025 · Cited by 572
Self-citationDNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation
Difilippantonio, M. J., Zhu, J., Chen, H. T., Meffre, E., Nussenzweig, M. C., Max, E. E., Ried, T., & Nussenzweig, A. (2000) · Nature · doi:10.1038/35006670 · Cited by 547
Research works printed but not linked: 1
- Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK . 2000 SEER Cancer Statistics Review, 1973–1997 National Cancer Institute: Bethesda
Cited by
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Self-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B., & Shaughnessy, J. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 698
Self-citationRaab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Genetics and Cytogenetics of Multiple Myeloma
Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J., Greipp, P. R., Kirsch, I. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2876 · Cited by 687
Self-citationAukema, S. M., Siebert, R., Schuuring, E., van Imhoff, G. W., Kluin-Nelemans, H. C., Boerma, E.-J., & Kluin, P. M. (2011) · Blood · doi:10.1182/blood-2010-09-297879 · Cited by 678
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
Self-citationMolecular Pathogenesis and a Consequent Classification of Multiple Myeloma
Bergsagel, P. L., & Kuehl, W. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.021 · Cited by 556
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
Cycling to Cancer with Cyclin D1
Diehl, J. A. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.72 · Cited by 475
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Carrasco, D. R., Tonon, G., Huang, Y., Zhang, Y., Sinha, R., Feng, B., Stewart, J. P., Zhan, F., Khatry, D., Protopopova, M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.019 · Cited by 425
Nuclear cyclin D1: an oncogenic driver in human cancer
Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.007 · Cited by 393
Self-citationKeats, J. J., Reiman, T., Maxwell, C. A., Taylor, B. J., Larratt, L. M., Mant, M. J., Belch, A. R., & Pilarski, L. M. (2003) · Blood · doi:10.1182/blood-2002-06-1675 · Cited by 382
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Ross, F. M., Avet-Loiseau, H., Ameye, G., Gutierrez, N. C., Liebisch, P., O'Connor, S., Dalva, K., Fabris, S., Testi, A. M., Jarosova, M., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.056176 · Cited by 322
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
Fonseca, R., Debes-Marun, C. S., Picken, E. B., Dewald, G. W., Bryant, S. C., Winkler, J. M., Blood, E., Oken, M. M., Santana-Dávila, R., González-Paz, N., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0493 · Cited by 296
Affer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., Garbitt, V. M., Riggs, D. L., Brents, L. A., Roschke, A. V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.70 · Cited by 268
Self-citationAnderson, K. C., & Carrasco, R. D. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130249 · Cited by 258
Difilippantonio, M. J., Petersen, S., Chen, H. T., Johnson, R., Jasin, M., Kanaar, R., Ried, T., & Nussenzweig, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020851 · Cited by 227
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis
Davies, F. E., Dring, A. M., Li, C., Rawstron, A. C., Shammas, M. A., O'Connor, S. M., Fenton, J. A. L., Hideshima, T., Chauhan, D., Tai, I. T., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0016 · Cited by 223
Interpretation of cytogenetic results in multiple myeloma for clinical practice
Rajan, A. M., & Rajkumar, S. V. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.92 · Cited by 219
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 209
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kyle, R. A. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.10.1371 · Cited by 209
Stewart, A. K., Bergsagel, P. L., Greipp, P. R., Dispenzieri, A., Gertz, M. A., Hayman, S. R., Kumar, S., Lacy, M. Q., Lust, J. A., Russell, S. J., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404516 · Cited by 207
Self-citationDiscovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing
Pflueger, D., Terry, S., Sboner, A., Habegger, L., Esgueva, R., Lin, P.-C., Svensson, M. A., Kitabayashi, N., Moss, B. J., MacDonald, T. Y., et al. (2011) · Genome Research · doi:10.1101/gr.110684.110 · Cited by 201
Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L. A., & Dalton, W. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2419 · Cited by 200
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma
Sawyer, J. R. (2011) · Cancer Genetics · doi:10.1016/j.cancergencyto.2010.11.002 · Cited by 198
Causes of oncogenic chromosomal translocation
Aplan, P. D. (2006) · Trends in Genetics · doi:10.1016/j.tig.2005.10.002 · Cited by 196
CDK4: A Key Player in the Cell Cycle, Development, and Cancer
Baker, S. J., & Reddy, E. P. (2012) · Genes & Cancer · doi:10.1177/1947601913478972 · Cited by 194
Plasma Cell Neoplasms: A Morphologic, Cytogenetic and Immunophenotypic Approach
(2016) · Springer eBooks · doi:10.1007/978-3-319-10918-3 · Cited by 194
Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q., Chen, C. I., Reece, D., Chun, K., & Keith Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04867.x · Cited by 193
Genetic events in the pathogenesis of multiple myeloma
Chng, W. J., Glebov, O., Bergsagel, P. L., & Kuehl, W. M. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.004 · Cited by 188
Self-citationWalker, B. A., Leone, P. E., Jenner, M. W., Li, C., Gonzalez, D., Johnson, D. C., Ross, F. M., Davies, F. E., & Morgan, G. J. (2006) · Blood · doi:10.1182/blood-2006-02-005496 · Cited by 187
A molecular compendium of genes expressed in multiple myeloma
Claudio, J. O., Masih-Khan, E., Tang, H., Gonçalves, J., Voralia, M., Li, Z. H., Nadeem, V., Cukerman, E., Francisco-Pabalan, O., Liew, C. C., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0008 · Cited by 185
Eisen, H. N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0029 · Cited by 184
Jungbluth, A. A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y.-T., Bhardwaj, N., Chen-Kiang, S., Old, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4931 · Cited by 182
Keats, J. J., Maxwell, C. A., Taylor, B. J., Hendzel, M. J., Chesi, M., Bergsagel, P. L., Larratt, L. M., Mant, M. J., Reiman, T., Belch, A. R., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3704 · Cited by 181
Self-citationDe Vos, J., Thykjær, T., Tarte, K., Ensslen, M., Raynaud, P., Requirand, G., Pellet, F., Pantesco, V., Rème, T., Jourdan, M., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205868 · Cited by 172
Molecular pathogenesis of multiple myeloma: basic and clinical updates
Chesi, M., & Bergsagel, P. L. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1291-2 · Cited by 170
Self-citationMolecular pathways in follicular lymphoma
Bende, R. J., Smit, L. A., & van Noesel, C. J. M. (2006) · Leukemia · doi:10.1038/sj.leu.2404426 · Cited by 167
Walker, B. A., Wardell, C. P., Johnson, D. C., Kaiser, M. F., Begum, D. B., Dahir, N. B., Ross, F. M., Davies, F. E., Gonzalez, D., & Morgan, G. J. (2013) · Blood · doi:10.1182/blood-2012-12-471888 · Cited by 166
FANCD2 Facilitates Replication through Common Fragile Sites
Madireddy, A., Kosiyatrakul, S. T., Boisvert, R. A., Herrera-Moyano, E., García-Rubio, M. L., Gerhardt, J., Vuono, E. A., Owen, N., Yan, Z., Olson, S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.017 · Cited by 165
Duquette, M. L., Pham, P., Goodman, M. F., & Maizels, N. (2005) · Oncogene · doi:10.1038/sj.onc.1208746 · Cited by 165
Kang, S., Dong, S., Gu, T.-L., Guo, A., Cohen, M. S., Lonial, S., Khoury, H. J., Fabbro, D., Gilliland, D. G., Bergsagel, P. L., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.003 · Cited by 164
Self-citationCell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 163
López‐Corral, L., Gutierrez, N. C., Vídriales, M., Mateos, M., Rasillo, A., García‐Sánz, R., Paiva, B., & Miguel, J. F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1066 · Cited by 162
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Barwick, B. G., Neri, P. E., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 162
Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Dalva-Aydemir, S., Bajpai, R., Martinez, M. S., Adekola, K., Kandela, I. K., Wei, C., Singhal, S., Koblinski, J. E., Raje, N. S., Rosen, S. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1088 · Cited by 153
Jenner, M. W., Leone, P., Walker, B. A., Ross, F. M., Johnson, D. C., de Castro, D. G., Chiecchio, L., Cabanas, E. D., Dagrada, G. P., Nightingale, M., et al. (2007) · Blood · doi:10.1182/blood-2007-02-075069 · Cited by 152
Lymphoma‐ and leukemia‐associated chromosomal translocations in healthy individuals
Janz, S., Potter, M., & Rabkin, C. S. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10178 · Cited by 149
Central nervous system myelomatosis: review of the literature
Nieuwenhuizen, L., & Biesma, D. H. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00956.x · Cited by 147
Mattioli, M., Agnelli, L., Fabris, S., Baldini, L., Morabito, F., Bicciato, S., Verdelli, D., Intini, D., Nobili, L., Cro, L., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208447 · Cited by 143
Albarracín, F., & Fonseca, R. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.01.005 · Cited by 142
Gozzetti, A., Cerase, A., Lotti, F., Rossi, D., Palumbo, A., Petrucci, M. T., Patriarca, F. F., Nozzoli, C., Cavo, M., Offidani, M., et al. (2011) · Cancer · doi:10.1002/cncr.26447 · Cited by 142
Rajkumar, S. V., Kyle, R. A., & Buadi, F. K. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0520 · Cited by 142
Characterization of 4 Mantle Cell Lymphoma Cell Lines: Establishment of an In Vitro Study Model
Amin, H. M., McDonnell, T. J., Medeiros, L. J., Rassidakis, G. Z., Leventaki, V., O’Connor, S. L., Keating, M. J., & Lai, R. L. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-0424-comclc · Cited by 140
Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma
Bergsagel, P. L., & Kuehl, W. M. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00052.x · Cited by 140
Self-citationTargeting cell cycle regulators in hematologic malignancies
Aleem, E. A., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 137
Characterization of MYC Translocations in Multiple Myeloma Cell Lines
Dib, A., Gabrea, A., Glebov, O. K., Bergsagel, P. L., & Kuehl, W. M. (2008) · JNCI Monographs · doi:10.1093/jncimonographs/lgn011 · Cited by 137
Self-citationHu, L., Ru, K., Zhang, L., Huang, Y.-T., Zhu, X., Liu, H., Zetterberg, A., Cheng, T., & Miao, W. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-3 · Cited by 134
Chang, H., Sloan, S. R., Li, D., & Stewart, A. K. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05199.x · Cited by 131
Plasma Cell Myeloma and Related Neoplasms
Lorsbach, R. B., Hsi, E. D., Doǧan, A., & Fend, F. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpenj68ffbriyb · Cited by 130
Revealing the Impact of Structural Variants in Multiple Myeloma
Rustad, E. H., Yellapantula, V. D., Głodzik, D., Maclachlan, K. H., Diamond, B. T., Boyle, E. M., Ashby, C., Blaney, P., Gundem, G., Hultcrantz, M. L., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0132 · Cited by 130
Large common fragile site genes and cancer
Smith, D. I., McAvoy, S., Zhu, Y., & Perez, D. S. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.003 · Cited by 129
Guillerey, C., Nakamura, K., Vučković, S., Hill, G. R., & Smyth, M. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2135-z · Cited by 128
McKenna, R. W., & Kroft, S. H. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7216-0040-6.00025-3 · Cited by 125
Specht, K., Haralambieva, E., Bink, K., Kremer, M., Mandl–Weber, S., Koch, I., Tomer, R., Höfler, H., Schuuring, E. M. D., Kluin, P. M., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3837 · Cited by 123
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells
Cheriyath, V., Glaser, K. B., Waring, J. F., Baz, R., Hussein, M. A., & Borden, E. C. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31122 · Cited by 122
Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance
Nikesitch, N., Lee, J. M., Ling, S., & Roberts, T. L. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1007 · Cited by 118
Zingone, A., & Kuehl, W. M. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.003 · Cited by 115
Self-citationMGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management
Rajkumar, S. V. (2005) · Hematology · doi:10.1182/asheducation-2005.1.340 · Cited by 114
Myc translocations in B cell and plasma cell neoplasms
Janz, S. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.017 · Cited by 112
Inoue, J., Otsuki, T., Hirasawa, A., Imoto, I., Matsuo, Y., Shimizu, S., Taniwaki, M., & Inazawa, J. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63276-2 · Cited by 109
A role for AID in chromosome translocations between c-myc and the IgH variable region
Dorsett, Y., Robbiani, D. F., Janković, M., Reina‐San‐Martin, B., Eisenreich, T., & Nussenzweig, M. C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070884 · Cited by 106
WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies
Aldaz, C. M., Ferguson, B. W., & Abba, M. C. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.06.001 · Cited by 105
Advances in Biology and Therapy of Multiple Myeloma
Barillé‐Nion, S., Barlogie, B., Bataille, R., Bergsagel, P. L., Epstein, J., Fenton, R. G., Jacobson, J. L., Kuehl, W. M., Shaughnessy, J. D., & Tricot, G. J. K. (2003) · Hematology · doi:10.1182/asheducation-2003.1.248 · Cited by 102
Self-citationJaksic, W., Trudel, S., Chang, H., Trieu, Y., Xi, Q., Mikhael, J. R., Reece, D. E., Chen, C. I., & Stewart, A. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.129 · Cited by 100
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC
Min, D.-J., Ezponda, T., Kim, M. K., Will, C., Martínez-García, E., Popovic, R., Basrur, V., Elenitoba‐Johnson, K. S. J., & Licht, J. D. (2012) · Leukemia · doi:10.1038/leu.2012.269 · Cited by 99
The malignant clone and the bone-marrow environment
Podar, K., Richardson, P. G. G., Hideshima, T., Chauhan, D., & Anderson, K. C. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.002 · Cited by 98
Gabrea, A., Martelli, M. L., Qi, Y., Roschke, A. V., Barlogie, B., Shaughnessy, J. D., Sawyer, J. R., & Kuehl, W. M. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20563 · Cited by 98
Self-citationYang, Y., & Cvekl, A. (2016) · Einstein Journal of Biology and Medicine · doi:10.23861/ejbm20072347 · Cited by 98
Moreau, P., Attal, M., Garban, F., Hulin, C., Facon, T. T. F., Marit, G., Michallet, M., Doyen, C., Leyvraz, S., Mohty, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404832 · Cited by 97
Chang, H., Qi, X., Trieu, Y., Xu, W., Reader, J. C., Ning, Y., & Reece, D. E. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06325.x · Cited by 96
Innate versus Adaptive Immunity: A Paradigm Past Its Prime?
Borghesi, L., & Milcarek, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0182 · Cited by 95
Early Genetic Events Provide the Basis for a Clinical Classification of Multiple Myeloma
Kuehl, W. M., & Bergsagel, P. L. (2005) · Hematology · doi:10.1182/asheducation-2005.1.346 · Cited by 95
Self-citationRajkumar, S. V. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.01.001 · Cited by 94
Chromosomal Translocations Involved in Non-Hodgkin Lymphomas
Vega, F., & Medeiros, L. J. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-1148-ctiinl · Cited by 94
Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma
Hájek, R., Okubote, S. A., & Šváchová, H. (2013) · British Journal of Haematology · doi:10.1111/bjh.12563 · Cited by 92
Shi, Y., Yang, Y., Hoang, B. Q., Bardeleben, C., Holmes, B., Gera, J., & Lichtenstein, A. K. (2015) · Oncogene · doi:10.1038/onc.2015.156 · Cited by 91
RetractedMolecular aspects of multiple myeloma
Pratt, G. (2002) · Molecular Pathology · doi:10.1136/mp.55.5.273 · Cited by 87
Paterson, J., Li, Z., Wen, X., Masih‐Khan, E., Chang, H., Pollett, J. B., Trudel, S., & Stewart, A. K. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04814.x · Cited by 86
Metadata
- Authors
- Bergsagel, P. L., & Kuehl, W. M.
- Affiliations
- Cornell University (US)
- National Cancer Institute (US)
- Corresponding author
- Bergsagel, P Leif
- ORCID
- Bergsagel, P Leif
- Venue
- Oncogene
- Published
- 2001-09-10
- Volume
- 20
- Issue
- 40
- Pages
- 5611-5622
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1977707370
- Cited by
- 478
- References
- 64
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 16 · 2022: 17 · 2021: 16 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 15 · 2016: 17 · 2015: 21 · 2014: 16 · 2013: 26 · 2012: 19
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multiple myeloma, chromosomal translocation, immunoglobulin heavy chain locus, monoclonal gammopathy of undetermined significance, cyclin D1, cyclin D3, FGFR3, MMSET, c-Maf, c-Myc, somatic hypermutation, tumor progression, extramedullary myeloma
- MeSH terms
- Cell Line, Transformed, Chromosomes, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 16, Chromosomes, Human, Pair 4, Chromosomes, Human, Pair 6, Chromosomes, Human, Pair 8, Humans, Immunoglobulins, Models, Genetic, Multiple Myeloma, Phenotype, Translocation, Genetic, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.